A doctor who recently led an agency inside the Department of Health of Human Services (HHS) filed a whistleblower complaint on Tuesday alleging leadership in the agency retaliated against him for voicing concerns about the response to the COVID-19 pandemic.
Dr. Rick Bright recently headed HHS Biomedical Advanced Research and Development Authority. The office is involved in developing a vaccine and analyzing possible treatments for COVID-19, a disease caused by the CCP (Chinese Communist Party) virus.
Bright was shifted to another agency last month. Bright said the transfer “was in response to my insistence that the government invest the billions of dollars allocated by Congress to address the COVID-19 pandemic into safe and scientifically vetted solutions, and not in drugs, vaccines, and other technologies that lack scientific merit.”
In the new complaint (pdf), Brights legal team said Bright objected to the promotion of hydroxychloroquine and chloroquine for treatment of COVID-19.
The two drugs were approved decades ago for treatment and prevention of malaria. Theyre being prescribed in hospitals around the world against COVID-19, which has no proven treatment or vaccine.
Bright “felt an urgent and compelling need to inform the American public that there was insufficient scientific data to support the use of these drugs for COVID-19 patients,” the complaint, filed with the Office of Special Counsel, states.
Bright was worried that the drugs largely came from factories outside the United States that hadnt been inspected by U.S. officials. Bright became frustrated with attempts to reason with his superiors and shared emails between HHS officials with a journalist, his lawyers said.
The “emails discussed the drugs potential toxicity and demonstrated the political pressure to rush these drugs from Pakistan and India to American households,” according to the complaint. “Dr. Bright hoped that by shining a light on HHSs reckless and dangerous push to make these drug available, American lives would be saved.”
The removal as BARDAs head stemmed from the push against hydroxychloroquinRead More From Source